跳至主要内容
临床试验/NCT01788995
NCT01788995已完成不适用

A Non-interventional Trial With Avastin as Front-line Treatment for Ovarian Cancer

Hoffmann-La Roche1 个研究点 分布在 1 个国家目标入组 63 人开始时间: 2012年10月15日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
63
试验地点
1
主要终点
Treatment discontinuations/modifications

研究概览

简要总结

This non-interventional study will evaluate the routine use and the safety and efficacy of Avastin (bevacizumab) as first-line treatment in patients with advanced ovarian cancer (epithelial ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma). Newly diagnosed patients who are initiated on carboplatin/paclitaxel chemotherapy in combination with Avastin will be followed for up to 15 months of treatment and 12 months of follow-up.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Adult patients, >/= 18 years of age
  • Patients with newly diagnosed advanced epithelial ovarian cancer (EOC), fallopian tube carcinoma (FTC) or primary peritoneal carcinomas (PPC) with indication for first-line carboplatin/paclitaxel chemotherapy in combination with Avastin

排除标准

  • Contraindications for Avastin according to the Summary of Product Characteristics

结局指标

主要结局

Treatment discontinuations/modifications

时间窗: approximately 4 years

Duration of treatment

时间窗: approximately 4 years

Clinical/demographic patient characteristics at initiation of treatment

时间窗: approximately 4 years

次要结局

  • Progression-free survival(approximately 4 years)
  • Safety: Incidence of adverse events(approximately 4 years)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验